These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 34498169

  • 21. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M, Maisnam I, Pal R, Mukhopadhyay S.
    Eur Heart J; 2023 Oct 01; 44(37):3686-3696. PubMed ID: 37605637
    [Abstract] [Full Text] [Related]

  • 22. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R, Schneeweiss S, Desai RJ.
    Eur Heart J; 2023 Jun 25; 44(24):2216-2230. PubMed ID: 37259575
    [Abstract] [Full Text] [Related]

  • 23. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
    Teo YH, Yoong CSY, Syn NL, Teo YN, Cheong JYA, Lim YC, Lee CH, Yeo TC, Chai P, Wong RCC, Lin W, Sia CH.
    Eur J Clin Pharmacol; 2021 Oct 25; 77(10):1453-1464. PubMed ID: 33942132
    [Abstract] [Full Text] [Related]

  • 24. The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kommu S.
    J Cardiovasc Pharmacol; 2024 Feb 01; 83(2):158-166. PubMed ID: 37989136
    [Abstract] [Full Text] [Related]

  • 25. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P, Bocchino PP, Angelini F, D'Ascenzo F, Galati G, Fysekidis M, DE Ferrari GM, Fischman DL, Bhatt DL, Biondi-Zoccai G.
    Minerva Cardiol Angiol; 2023 Apr 01; 71(2):199-207. PubMed ID: 35195376
    [Abstract] [Full Text] [Related]

  • 26. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
    Tian L, Ai S, Zheng H, Yang H, Zhou M, Tang J, Liu W, Zhao W, Wang Y.
    Front Pharmacol; 2022 Apr 01; 13():986186. PubMed ID: 36506550
    [Abstract] [Full Text] [Related]

  • 27. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
    Camilli M, Lombardi M, Chiabrando JG, Zito A, Del Buono MG, Vergallo R, Aspromonte N, Lombardo A, Montone RA, Niccoli G, Biondi-Zoccai G, Crea F, Minotti G.
    Am J Ther; 2021 Nov 24; 29(2):e199-e204. PubMed ID: 35389572
    [Abstract] [Full Text] [Related]

  • 28. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
    Zheng S, Lai Y, Jiang C, He L, Zhao Z, Li W, Tang R, Sang C, Long D, Du X, Ma C, Dong J.
    Pacing Clin Electrophysiol; 2024 Jan 24; 47(1):58-65. PubMed ID: 38010824
    [Abstract] [Full Text] [Related]

  • 29. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ, Zhang ZY, Yan Q, Cao HL, Zhao YJ, Yang B, Li J.
    ESC Heart Fail; 2023 Apr 24; 10(2):1314-1325. PubMed ID: 36722326
    [Abstract] [Full Text] [Related]

  • 30. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Lancet; 2019 Jan 05; 393(10166):31-39. PubMed ID: 30424892
    [Abstract] [Full Text] [Related]

  • 31. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X, Zhang Q, Zhu L, Wang G, Ge P, Hu A, Sun X.
    Int J Cardiol; 2021 Jun 01; 332():119-126. PubMed ID: 33838152
    [Abstract] [Full Text] [Related]

  • 32. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK, Singh A, Singh R.
    Endocr Pract; 2023 Jul 01; 29(7):509-516. PubMed ID: 37037286
    [Abstract] [Full Text] [Related]

  • 33. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H.
    Am J Med; 2020 Nov 01; 133(11):e625-e630. PubMed ID: 32389659
    [Abstract] [Full Text] [Related]

  • 34. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
    Kani R, Watanabe A, Miyamoto Y, Ejiri K, Iwagami M, Takagi H, Slipczuk L, Tsugawa Y, Aikawa T, Kuno T.
    J Am Heart Assoc; 2024 Feb 06; 13(3):e031805. PubMed ID: 38293914
    [Abstract] [Full Text] [Related]

  • 35. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
    Qiu M, Ding LL, Zhou HR.
    Am J Cardiovasc Drugs; 2022 Jan 06; 22(1):69-81. PubMed ID: 34231123
    [Abstract] [Full Text] [Related]

  • 36. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 37. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials.
    Lee MC, Hua YM, Yang CT, Kuo FH, Chang WT, Tang HJ, Siong Toh H, Lin YM, Chen SY, Chang HY, Liao CT.
    Medicine (Baltimore); 2022 Dec 23; 101(51):e32489. PubMed ID: 36595871
    [Abstract] [Full Text] [Related]

  • 38. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhao Z, Jin P, Zhang Y, Hu X, Tian C, Liu D.
    Front Cardiovasc Med; 2022 Dec 23; 9():826684. PubMed ID: 35557542
    [Abstract] [Full Text] [Related]

  • 39. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, Li G, Lip GYH, Liu T.
    Eur J Prev Cardiol; 2022 Feb 03; 28(17):1961-1973. PubMed ID: 34792124
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.